<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04812912</url>
  </required_header>
  <id_info>
    <org_study_id>21-035</org_study_id>
    <nct_id>NCT04812912</nct_id>
  </id_info>
  <brief_title>Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer</brief_title>
  <official_title>The Effects of Chemotherapy or Radiotherapy on Reproductive and Sexual Health of Early Onset Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out how cancer treatments (chemotherapy and/or radiation&#xD;
      therapy) affect reproductive and sexual health in people with early onset colorectal cancer.&#xD;
      The study researchers will observe and track changes in hormone levels and in sexual and&#xD;
      reproductive health in people with early onset colorectal cancer. This information will help&#xD;
      researchers know more about how cancer treatments affect reproductive and sexual health,&#xD;
      including the ability to have children (fertility).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">March 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 18, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in anti-Mullerian hormone (AMH), estradiol and FSH of oxaliplatin-induced gonadal toxicity in pre-menopausal female patients (&lt;40y)</measure>
    <time_frame>Up to 30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH in young male patients (&lt;50y) undergoing therapy for colorectal cancer</measure>
    <time_frame>Up to 30 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Participants with Colon Cancer</arm_group_label>
    <description>This patient population will have hormone biomarker analysis, questionnaire (QOL) administration, and, if the patient is male, semen analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with Rectal Cancer</arm_group_label>
    <description>This patient population will have hormone biomarker analysis, QOL administration, and, if the patient is male, semen analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hormone biomarker analysis</intervention_name>
    <description>For female patients, hormone biomarker analysis will be performed to measure: anti-Mullerian hormone (AMH), estradiol and FSH in the blood. In male patients, hormone biomarkers of testicular function and spermatogenesis will be monitored: testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH. Sperm analysis will also be performed in male patients to monitor changes in sperm count.</description>
    <arm_group_label>Participants with Colon Cancer</arm_group_label>
    <arm_group_label>Participants with Rectal Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>QoL Questionnaires</intervention_name>
    <description>All participants will respond to protocol questionnaires, which will include both validated questionnaires as well as non-validated ones. This design will allow for basic demographic, psychosocial and sexual-health-related data to be obtained.</description>
    <arm_group_label>Participants with Colon Cancer</arm_group_label>
    <arm_group_label>Participants with Rectal Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential research subjects will be identified through the Center for Young Onset&#xD;
        Colorectal Cancer, a member of the patient's treatment team, the principal investigator, or&#xD;
        research team at Memorial Sloan Kettering Cancer Center (MSKCC). All study participants&#xD;
        will be recruited from patients under the care of consenting professionals. If the&#xD;
        investigator is a member of the treatment team, s/he will screen their patient's medical&#xD;
        records for suitable research study participants and discuss the study and their potential&#xD;
        for enrolling in the research study. Potential subjects contacted by their treating&#xD;
        physician will be referred to the investigator/research staff of the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-40 years of age and premenopausal (female) or 18-50 years of age (male) at time of&#xD;
             diagnosis&#xD;
&#xD;
          -  Histologic diagnosis of colorectal adenocarcinoma&#xD;
&#xD;
          -  Able and willing to participate in the informed consent process&#xD;
&#xD;
          -  Eligible for curative adjuvant or neoadjuvant therapy for colon or rectal cancer&#xD;
&#xD;
          -  Willing and able to complete protocol questionnaires&#xD;
&#xD;
          -  Rectal patients only: Individuals who will be receiving chemotherapy, followed by&#xD;
             chemoradiotherapy (ChemoRT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic treatment for this malignancy&#xD;
&#xD;
          -  Active or prior secondary malignancy&#xD;
&#xD;
          -  History of ovarian resection (if female)&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception until the termination of gestation, confirmed by a positive&#xD;
             hCG laboratory test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Cercek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Cercek, MD</last_name>
    <phone>646-888-4189</phone>
    <email>cerceka@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Romesser, MD</last_name>
    <phone>646-888-2118</phone>
    <email>romessep@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center at Suffolk - Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early Onset Colorectal Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>21-035</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

